757247-76-0

Upstream product

• 757247-74-8 (2R,3S)-N-tert-Butyloxycarbonyl-3-(tert-butyldimethylsilanyloxy)-2-((1S)-1-aminoethyl)-pyrrolidine 
• 757247-75-9 2-chloro-4-iodo-3-methylbenzonitrile 
• 573768-09-9 4-amino-2-chloro-3-methyl-benzonitrile 
• 850003-05-3 (2S,3S)-N-tert-butyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-pyrrolidinecarboxylic acid methyl ester 
• 757247-71-5 tert-butyl (2S,3S)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-formylpyrrolidine-1-carboxylate 
• 864271-14-7 (2R,3S)-N-tert-Butyloxycarbonyl-3-(tert-butyldimethylsilanyloxy)-2-(1-hydroxyethyl)-pyrrolidine 
• 757247-72-6 (2S,3S)-N-tert-butyloxycarbonyl-3-(tert-butyldimethylsilanyloxy)-2-(1-hydroxyethyl)-pyrrolidine 
• 757247-73-7 C₁₇H₃₄N₂O₄Si 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 156129-73-6 tert-butyl (2R,3S)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 184046-78-4 (2S,3S)-1-tert-butyl-2-methyl 3-hydroxypyrrolidine-1,2-dicarboxylate 
• 627531-48-0 N-(3-chloro-4-cyano-2-methylphenyl)acetamide 
• 7463-35-6 N-(3-chloro-2-methylphenyl)acetamide 
• 125328-80-5 N-(4-bromo-3-chloro-2-methylphenyl)acetamide 

Downstream Products

• 757247-77-1 4-((S)-1-((2R,3S)-3-(tert-butyldimethylsilanyloxy)pyrrolidin-2-yl)ethylamino)-2-chloro-3-methylbenzonitrile 
• 950585-89-4 C₂₀H₃₀N₃SO₃SiCl 
• 863204-90-4 (2R,3S)-3-(tert-butyldimethylsilanyloxy)-2-[(1S)-1-(3-chloro-4-cyano-2-methyl-phenylamino)-ethyl]pyrrolidine, trifluoroacetic acid salt 
• 757247-34-0 2-chloro-4-((1S,7S,7aR)-7-hydroxy-1-methyl-3-oxo-tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-3-methylbenzonitrile 
• 757247-78-2 C₂₁H₃₀ClN₃O₂Si 

Relevant academic research and scientific papers

Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications

A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR Ki = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.

Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators

Replacement of the 3-oxo group of 2-chloro-4-[(7R,7aS)-7-hydroxy-1,3-dioxotetrahydro-1H-pyrrolo[1,2c]imidazol-2(3H)-yl]-3-methylbenzonitrile resulted in a sulfamide series of selective androgen receptor modulator (SARM) agonists.

BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.

BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION

The invention provides compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.